Logo image of SLS

SELLAS LIFE SCIENCES GROUP I (SLS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLS - US81642T2096 - Common Stock

1.55 USD
+0.02 (+1.31%)
Last: 11/24/2025, 8:26:21 PM
1.55 USD
0 (0%)
Pre-Market: 11/25/2025, 8:12:17 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to SLS. SLS was compared to 533 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SLS as it has an excellent financial health rating, but there are worries on the profitability. SLS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SLS has reported negative net income.
In the past year SLS has reported a negative cash flow from operations.
In the past 5 years SLS always reported negative net income.
In the past 5 years SLS always reported negative operating cash flow.
SLS Yearly Net Income VS EBIT VS OCF VS FCFSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

SLS has a worse Return On Assets (-81.28%) than 67.73% of its industry peers.
SLS's Return On Equity of -100.42% is in line compared to the rest of the industry. SLS outperforms 46.72% of its industry peers.
Industry RankSector Rank
ROA -81.28%
ROE -100.42%
ROIC N/A
ROA(3y)-319.06%
ROA(5y)-214.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLS Yearly ROA, ROE, ROICSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLS Yearly Profit, Operating, Gross MarginsSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for SLS has been increased compared to 1 year ago.
Compared to 5 years ago, SLS has more shares outstanding
There is no outstanding debt for SLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SLS Yearly Shares OutstandingSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SLS Yearly Total Debt VS Total AssetsSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

SLS has an Altman-Z score of 2.71. This is not the best score and indicates that SLS is in the grey zone with still only limited risk for bankruptcy at the moment.
SLS has a better Altman-Z score (2.71) than 69.61% of its industry peers.
There is no outstanding debt for SLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.71
ROIC/WACCN/A
WACCN/A
SLS Yearly LT Debt VS Equity VS FCFSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

2.3 Liquidity

SLS has a Current Ratio of 4.91. This indicates that SLS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.91, SLS perfoms like the industry average, outperforming 55.91% of the companies in the same industry.
SLS has a Quick Ratio of 4.91. This indicates that SLS is financially healthy and has no problem in meeting its short term obligations.
SLS's Quick ratio of 4.91 is in line compared to the rest of the industry. SLS outperforms 56.85% of its industry peers.
Industry RankSector Rank
Current Ratio 4.91
Quick Ratio 4.91
SLS Yearly Current Assets VS Current LiabilitesSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 59.42% over the past year.
EPS 1Y (TTM)59.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SLS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.51% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y48.33%
EPS Next 2Y15.62%
EPS Next 3Y11.03%
EPS Next 5Y40.51%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLS Yearly Revenue VS EstimatesSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2020 2021 2022 2023 2026 2027 2028 2029 2030 2031 200M 400M 600M
SLS Yearly EPS VS EstimatesSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -2K -4K -6K -8K -10K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLS Price Earnings VS Forward Price EarningsSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLS Per share dataSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.62%
EPS Next 3Y11.03%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SELLAS LIFE SCIENCES GROUP I

NASDAQ:SLS (11/24/2025, 8:26:21 PM)

Premarket: 1.55 0 (0%)

1.55

+0.02 (+1.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-18 2026-03-18/amc
Inst Owners25.55%
Inst Owner Change22.88%
Ins Owners0.25%
Ins Owner Change4.56%
Market Cap163.22M
Revenue(TTM)N/A
Net Income(TTM)-26.26M
Analysts82.86
Price Target6.97 (349.68%)
Short Float %27.6%
Short Ratio7.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.91%
Min EPS beat(2)15.82%
Max EPS beat(2)33.99%
EPS beat(4)4
Avg EPS beat(4)24.96%
Min EPS beat(4)15.82%
Max EPS beat(4)33.99%
EPS beat(8)5
Avg EPS beat(8)-1249.76%
EPS beat(12)7
Avg EPS beat(12)-838.68%
EPS beat(16)7
Avg EPS beat(16)-642.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)24.42%
EPS NY rev (1m)0%
EPS NY rev (3m)22.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.24
P/tB 6.73
EV/EBITDA N/A
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.34
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.25
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -81.28%
ROE -100.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-319.06%
ROA(5y)-214.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.91
Quick Ratio 4.91
Altman-Z 2.71
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y48.33%
EPS Next 2Y15.62%
EPS Next 3Y11.03%
EPS Next 5Y40.51%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y3.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.96%
OCF growth 3YN/A
OCF growth 5YN/A

SELLAS LIFE SCIENCES GROUP I / SLS FAQ

What is the fundamental rating for SLS stock?

ChartMill assigns a fundamental rating of 2 / 10 to SLS.


What is the valuation status of SELLAS LIFE SCIENCES GROUP I (SLS) stock?

ChartMill assigns a valuation rating of 0 / 10 to SELLAS LIFE SCIENCES GROUP I (SLS). This can be considered as Overvalued.


How profitable is SELLAS LIFE SCIENCES GROUP I (SLS) stock?

SELLAS LIFE SCIENCES GROUP I (SLS) has a profitability rating of 0 / 10.


Is the dividend of SELLAS LIFE SCIENCES GROUP I sustainable?

The dividend rating of SELLAS LIFE SCIENCES GROUP I (SLS) is 0 / 10 and the dividend payout ratio is 0%.